|Bid||57.980 x 900|
|Ask||58.170 x 1000|
|Day's Range||55.550 - 58.830|
|52 Week Range||26.540 - 58.830|
|PE Ratio (TTM)||N/A|
|Earnings Date||Jul 30, 2018 - Aug 3, 2018|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||39.58|
Neogen (NEOG) sticks to its four-pronged growth strategy for steady progress. Also, the company's accretive buyouts and its broader international base are a boon.
Abbott (ABT) posts another quarter of strong EPD and Medical Devices performance. Particularly, Abbott has been riding high on a healthy growth within its Diabetes Care business.
The FDA defers decision regarding label expansion application to include cardiovascular indication on the label of J&J's (JNJ) diabetes drug Invokana.
Achillion (ACHN) commences a first-in-human phase I study on ACH-5548, a next-generation, oral small-molecule factor D inhibitor.
With the adoption of Abaxis' (ABAX) point-of-care diagnostic instruments post acquisition, the combined entity's veterinary diagnostics category should grow faster than the animal health industry.
We create a strategy that singles out less-risky stocks which can generate impressive returns only when certain parameters are considered.
Here we take a quick look at the major factors that have been plaguing Wright Medical and discuss the prospects that ensure near-term recovery.
The FDA grants a priority review to Pfizer's (PFE) NDA for leukemia candidate glasdegib for the first-line treatment of acute myeloid leukemia (AML) in combination with chemotherapy.
Masimo's (MASI) Eve with Rad-97 Pulse CO-Oximeter to be integrated in nine hospitals across UAE for CCHD screening in newborns.
Walgreens Boots (WBA) is upbeat about the recent acquisition of stores from Rite Aid which has already started to strengthen its U.S. pharmacies business.
Testing could lead to extension of life through improved clinical decision-making by identifying patients who need to switch from targeted hormonal therapy to chemotherapy NEW YORK and SAN DIEGO , June ...